FDA clears first-of-a-kind device for brain cancer

Apr 15, 2011

(AP) -- Medical device maker Novocure says it has received U.S. approval for a first-of-a-kind treatment which fights cancerous brain tumors using electrical energy fields.

The Food and Drug Administration has approved the device for patients with aggressive brain cancer that has returned after treatment with chemotherapy. Patients with recurring brain cancer usually live only a few months.

For decades doctors have treated cancer with drugs, and surgery. Novocure's NovoTTF offers a fourth approach. The portable device uses electric fields to disrupt the division of that allows tumors to grow. It sends the signals through four electrodes which are taped to the patient's head.

A 237-patient study showed that people using the device lived about as long as those taking . However, patients had significantly fewer side effects.

Explore further: Endogenous hormones improve breast cancer risk models

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Clinical Trial to Treat Brain Tumors with Electric Fields

Jun 04, 2010

(PhysOrg.com) -- The University of Illinois at Chicago is taking part in an international, multi-center study for patients newly diagnosed with the most common and aggressive type of brain tumor, glioblastoma multiforme, ...

Clinical trial evaluating brain cancer vaccine is underway

Oct 19, 2007

A clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has begun at NYU Medical Center. The study will evaluate the addition of the vaccine following standard therapy with surgery ...

Drug combination shrinks breast cancer metastases in brain

Dec 16, 2007

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber ...

Recommended for you

Endogenous hormones improve breast cancer risk models

13 hours ago

(HealthDay)—Inclusion of endogenous hormones in prediction models improves prediction of invasive breast cancer risk in postmenopausal women, according to a study published online Aug. 18 in the Journal of ...

Novel oncogenic RET mutation found in small cell lung cancer

14 hours ago

For the first time an oncogenic somatic mutation at amino acid 918 in the RET (rearranged during transfection) protein has been identified in small cell lung cancer (SCLC) tumors and enforced expression of this mutation within ...

User comments : 0